BIOSPAIN 2026: Full Schedule

14:30 CEST

Spanish biotech spin-offs and their integration into the global ecosystem: reaching out and attracting EU, US and Asia players

Tuesday September 29, 2026 14:30 - 15:15 CEST

4 Raúl Martín room

Spanish biotech spin-offs are stepping onto the global stage like nimble launchpads of innovation, pulling in investors and partners from Europe, the US and Asia. Rooted in world-class science yet built for translation, they marry academic brilliance with entrepreneurial grit — and with sharper international branding, smoother regulatory pathways and bolder cross-border alliances, they can turn local discoveries into scalable, globe-spanning solutions.

Moderators

Emilio Erazo Fischer

Operating Partne, Asabys Partners

Operating partner at Asabys, Emilio joined the team in December 2024. Emilio supports our biopharma portfolio investments in strategy and business development and currently holds the CBO role at ALLOX.Previously, Emilio led external innovation deals at Boehringer Ingelheim, as Director of Global BD&L Oncology, contributing novel pipeline assets and technology platforms. Emilio has fostered pharma-biotech relationships across Europe, the US and Japan, and served as consultant for... Read More →

Speakers

Hakan Goker

Managing Director, Merck Ventures B.V.

Hakan Goker, PhD, is Managing Director of M Ventures and heads the Biotechnology Investments covering Healthcare and Life Sciences. Hakan joined M Ventures in 2013 and has been investing in the sector for 18 years. Previously, Hakan was a partner at Aescap Venture investing in European... Read More →

Marc Martinell

CEO, Minoryx Therapeutics

Marc Martinell is the founder and CEO of Minoryx Therapeutics, a Spanish biotechnology company specializing in the development of innovative treatments for rare diseases of the central nervous system (CNS). Martinell has also worked at other companies in the sector, such as Oryzon... Read More →

Alice Zhang

Senior Director Strategy, WuXi AppTec

Prabhu Velusami

Senior Director S&E EMEA, Johnson & Johnson

Dr Prabhu Velusami is Senior Director of New Ventures and Transactions for Johnson & Johnson Innovation and is located in the Innovation Centre in London. He leads the identification and sourcing of early stage transformative innovation, and the subsequent shaping and execution of... Read More →

Tuesday September 29, 2026 14:30 - 15:15 CEST
4 Raúl Martín room

Round table discussion

Audience English language
Subject Call for sessions, Asabys Partners
Track Finance & investment

15:15 CEST

Current innovation trends in therapeutic technologies and modalities: what is the potential of Spain to ride these waves?

Wednesday September 30, 2026 15:15 - 16:00 CEST

2 Dorotea Barnés room

Mapping where the next therapeutic breakthroughs are emerging in Spain—key institutions, technologies and talent—and how to access and translate them into investment and company-building opportunities.

A guided tour of Spain’s biomedical frontier: where tomorrow’s therapies are being born, who’s driving them, which technologies enable them, and how to convert those breakthroughs into investment and company-building opportunities

Moderators

Montserrat Vendrell

Partner, Asabys Partners

Montse currently serves on the board of directors of Ona Therapeutics, InBrain Neuroelectronics, Peptomyc and Accure. She is also independent director at the board of Oryzon genomics.Formerly, Montse was partner at Aliath Bioventures and Alta Life Sciences. Prior to that, she was... Read More →

Speakers

Gloria González

Researcher / CSO, CIMA / Amets Biotechnology

She holds a degree in Biology from the University of the Basque Country. She earned her PhD from the Autonomous University of Madrid after completing her doctoral thesis at the Center for Biological Research (CBI) of the Spanish National Research Council (CSIC) in Madrid, under the... Read More →

Pilar Carrato

Director of finance and innovation, CDTI

She began her professional career as a financial analyst at the Bank of Spain.

Subsequently, she developed her financial career in various securities and stock exchange firms in their international departments for 12 years, eventually becoming Head of Sales and Trading at BCH and... Read More →

Robert Fabregat

CEO, BIOCAT

Robert Fabregat (Barcelona, 1980) holds a degree in Chemistry and a PhD in Pharmacy from the University of Barcelona (UB), as well as a Master’s degree in Project Management from BES-La Salle and specific training in Strategy and Innovation from ESADE. From 2019 to 2021, he was... Read More →

Gurutz Linazasoro

Founder, VIVEbiotech

Gurutz es neurólogo especializado en enfermedad de Parkinson y trastornos neurodegenerativos. Es Director del Programa de Terapias Avanzadas para el Alzheimer y Parkinson del Grupo Quirón Salud-Policlínica Gipuzkoa, y Director del Curso Nacional Anual sobre Trastornos del Movimiento.Gurutz... Read More →

Wednesday September 30, 2026 15:15 - 16:00 CEST
2 Dorotea Barnés room

Round table discussion

Audience English language
Subject Call for sessions, Asabys Partners
Track Finance & investment

14:30 CEST

15:15 CEST

Get help with the event